Contact SRI Biosciences

Center for Infectious Disease and Biodefense Research

Infectious diseases truly represent a global public health challenge; therefore, the discovery of safe and effective therapeutics is imperative. At SRI, we bring a wealth of experience and diverse scientific interests to our mission of creating improved diagnostics, prophylactics and therapeutics for a wide range of rare and neglected diseases and tropical diseases, and infectious and biological threat agents, all of which seriously challenge global health. Our capabilities include medicinal and synthetic chemistry; in vitro assay development; and in vitro and in vivo drug efficacy screening against toxins and bacterial, viral, and parasitic diseases (including CDC select agents) up to BSL3 containment.

Learn more about our research in infectious disease from Ellen Beaulieu.

Read about preclinical effectiveness of new drug targets for the treatment of tuberculosis.

Listen to NPR's Science Friday interview with Rajeev Vaidyanathan as he reveals new research findings on bed bugs.

In Vitro Efficacy Models

• Neglected & emerging pathogens
  • (Mycobacterium tuberculosis) drug screening, including XDR/MDR strains
  • Influenza virus strains
  • Parasitic diseases, including Leishmaniasis and Chagas
• Drug-resistant bacterial pathogens:
  • HA and CA-MRSA, Acinetobacter spp., Klebsiella spp., Pseudomonas spp.
• NIAID category A, B and C pathogens and select agents:
  • B.anthracis, Y. pestis, F. tularensis, Burkholderia spp, C.burnetii, Brucella spp., Chlamydia spp., Shigella spp., Rickettsia spp., Listeria spp, Vibrio spp.
  • Viruses including dengue, SARS, arenaviruses, Hantaan, Rift Valley Fever, West Nile, Chikungunya, and other encephalitis-causing viruses
  • Toxins including ricin, botulinum, shiga and Staphylococcus enterotoxin B
• Food-borne pathogens including Salmonella and enterohemorrhagic E. coli
• Host response profiles following host-pathogen interaction

In Vivo Efficacy Models

• Infectious disease model development
• Mouse and ferret models of influenza infection
• Small animal imaging
• Sepsis models

Vector Biology

• Insecticide resistance
• Vector competence
• Entomotherapeutics, the application of insect-derived compounds as novel therapies

Customized Assay Development and Screening

Biomarker Discovery Diagnostic Development

Contact SRI Biosciences

       Last Updated Dec 12, 2011